BlackRock Inc. grew its position in shares of Orthopediatrics Corp (NASDAQ:KIDS) by 12.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 455,657 shares of the company’s stock after buying an additional 50,179 shares during the quarter. BlackRock Inc. owned approximately 3.56% of Orthopediatrics worth $15,894,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently modified their holdings of the company. We Are One Seven LLC bought a new stake in Orthopediatrics during the fourth quarter worth about $39,000. Bank of Montreal Can grew its stake in Orthopediatrics by 4,156.3% during the fourth quarter. Bank of Montreal Can now owns 2,043 shares of the company’s stock worth $71,000 after buying an additional 1,995 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new stake in Orthopediatrics during the fourth quarter worth about $168,000. Rhumbline Advisers bought a new stake in Orthopediatrics during the third quarter worth about $207,000. Finally, Renaissance Technologies LLC bought a new stake in Orthopediatrics during the third quarter worth about $242,000. 44.82% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts have weighed in on the stock. Zacks Investment Research raised shares of Orthopediatrics from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research note on Saturday, March 16th. BidaskClub upgraded shares of Orthopediatrics from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 1st. BTIG Research upped their target price on shares of Orthopediatrics to $44.00 and gave the stock a “buy” rating in a research report on Friday, March 8th. Finally, JMP Securities assumed coverage on shares of Orthopediatrics in a research report on Wednesday, February 20th. They set an “outperform” rating and a $44.00 target price on the stock. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $41.00.
Shares of KIDS stock opened at $38.01 on Wednesday. Orthopediatrics Corp has a 1 year low of $17.97 and a 1 year high of $47.82. The company has a market cap of $562.43 million, a PE ratio of -39.59 and a beta of 0.18. The company has a current ratio of 10.54, a quick ratio of 7.77 and a debt-to-equity ratio of 0.26.
Orthopediatrics (NASDAQ:KIDS) last announced its earnings results on Wednesday, March 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.19). Orthopediatrics had a negative net margin of 20.89% and a negative return on equity of 22.99%. The company had revenue of $14.60 million for the quarter, compared to analyst estimates of $14.50 million. During the same period in the prior year, the business earned ($1.41) earnings per share. Orthopediatrics’s quarterly revenue was up 24.8% on a year-over-year basis. Research analysts predict that Orthopediatrics Corp will post -0.41 EPS for the current year.
Orthopediatrics Company Profile
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.
Further Reading: Commodities
Want to see what other hedge funds are holding KIDS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orthopediatrics Corp (NASDAQ:KIDS).
Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.